Seattle, WA, United States of America

Hongjie Wang

USPTO Granted Patents = 8 

 

Average Co-Inventor Count = 2.1

ph-index = 4

Forward Citations = 29(Granted Patents)


Company Filing History:


Years Active: 2014-2023

Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: Innovations and Contributions of Inventor Hongjie Wang

Introduction

Hongjie Wang is a prominent inventor based in Seattle, WA. He has made significant contributions to the field of biomedical research, particularly in the development of innovative therapeutic approaches. With a total of 8 patents to his name, Wang's work has had a substantial impact on the treatment of disorders associated with epithelial tissues.

Latest Patents

Among his latest patents is the invention related to Desmoglein 2 (DSG2) binding proteins and their uses. This invention provides recombinant adenoviral compositions and methods for their application in treating disorders associated with epithelial tissues. The focus on DSG2 binding proteins highlights Wang's commitment to advancing medical science and improving patient outcomes.

Career Highlights

Wang has had a distinguished career, working at notable institutions such as the University of Washington and Compliment Corporation. His research has been pivotal in exploring new avenues for therapeutic interventions, particularly in the realm of gene therapy and targeted treatments.

Collaborations

Wang has collaborated with esteemed colleagues, including Andre Lieber and André Lieber. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to groundbreaking discoveries.

Conclusion

In summary, Hongjie Wang's contributions to the field of biomedical research through his patents and collaborations underscore his role as a leading inventor. His work continues to inspire advancements in medical treatments and therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…